Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Kiang

Showing results (41-50 of 61) with videos related to

Pageof 7
Sort By:
Biological Psychology|April 8, 2017
Abnormal self-schema in semantic memory in major depressive disorder: Evidence from event-related brain potentialsMichael Kiang, Faranak Farzan, Daniel M Blumberger, et al.
Clinical EEG and Neuroscience|December 28, 2020
Decreased Gamma Auditory Steady-State Response Is Associated With Impaired Real-World Functioning in Unmedicated Patients at Clinical High Risk for PsychosisSarah Ahmed, Jennifer R Lepock, Romina Mizrahi, et al.
Schizophrenia Bulletin|October 17, 2017
Nigral Stress-Induced Dopamine Release in Clinical High Risk and Antipsychotic-Naïve SchizophreniaHuai-Hsuan Tseng, Jeremy J Watts, Michael Kiang, et al.
Plos One|July 18, 2024
A mixed-methods study to evaluate the feasibility and preliminary efficacy of delivering the optimal health program (OHP) for youth at clinical high risk (CHR) for psychosis: A study protocolMuhammad Omair Husain, Lisa D Hawke, Yun Lu, et al.
Clinical EEG and Neuroscience|March 6, 2018
Using Mismatch Negativity to Investigate the Pathophysiology of Substance Use Disorders and Comorbid PsychosisJessica U Ramlakhan, Reza Zomorrodi, Jonathan Downar, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|August 9, 2018
Hippocampal glutamate metabolites and glial activation in clinical high risk and first episode psychosisShima Shakory, Jeremy J Watts, Sina Hafizi, et al.
Brain : a Journal of Neurology|June 4, 2018
Cortical stress regulation is disrupted in schizophrenia but not in clinical high risk for psychosisChristin Schifani, Huai-Hsuan Tseng, Miran Kenk, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|April 7, 2026
Optimizing Health for Canadian Youth at Clinical High Risk for Psychosis: A Feasibility Study: Optimiser la santé des jeunes Canadiens présentant un risque clinique élevé de psychose : Une étude de faisabilitéYun Lu, Beatrice Todesco, Lisa D Hawke, et al.
Brain, Behavior, & Immunity - Health|March 18, 2024
Neurofilament light-chain (NfL) and 18 kDa translocator protein in early psychosis and its putative high-riskKankana Nisha Aji, Giulia Cisbani, Ana Weidenauer, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 13, 2017
Imaging Microglial Activation in Individuals at Clinical High Risk for Psychosis: an In Vivo PET Study with [<sup>18</sup>F]FEPPASina Hafizi, Tania Da Silva, Cory Gerritsen, et al.
Pageof 7

Showing results (41-50 of 61) with videos related to

Sort By:
Pageof 7
Biological Psychology|April 8, 2017
Abnormal self-schema in semantic memory in major depressive disorder: Evidence from event-related brain potentialsMichael Kiang, Faranak Farzan, Daniel M Blumberger, et al.
Clinical EEG and Neuroscience|December 28, 2020
Decreased Gamma Auditory Steady-State Response Is Associated With Impaired Real-World Functioning in Unmedicated Patients at Clinical High Risk for PsychosisSarah Ahmed, Jennifer R Lepock, Romina Mizrahi, et al.
Schizophrenia Bulletin|October 17, 2017
Nigral Stress-Induced Dopamine Release in Clinical High Risk and Antipsychotic-Naïve SchizophreniaHuai-Hsuan Tseng, Jeremy J Watts, Michael Kiang, et al.
Plos One|July 18, 2024
A mixed-methods study to evaluate the feasibility and preliminary efficacy of delivering the optimal health program (OHP) for youth at clinical high risk (CHR) for psychosis: A study protocolMuhammad Omair Husain, Lisa D Hawke, Yun Lu, et al.
Clinical EEG and Neuroscience|March 6, 2018
Using Mismatch Negativity to Investigate the Pathophysiology of Substance Use Disorders and Comorbid PsychosisJessica U Ramlakhan, Reza Zomorrodi, Jonathan Downar, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|August 9, 2018
Hippocampal glutamate metabolites and glial activation in clinical high risk and first episode psychosisShima Shakory, Jeremy J Watts, Sina Hafizi, et al.
Brain : a Journal of Neurology|June 4, 2018
Cortical stress regulation is disrupted in schizophrenia but not in clinical high risk for psychosisChristin Schifani, Huai-Hsuan Tseng, Miran Kenk, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|April 7, 2026
Optimizing Health for Canadian Youth at Clinical High Risk for Psychosis: A Feasibility Study: Optimiser la santé des jeunes Canadiens présentant un risque clinique élevé de psychose : Une étude de faisabilitéYun Lu, Beatrice Todesco, Lisa D Hawke, et al.
Brain, Behavior, & Immunity - Health|March 18, 2024
Neurofilament light-chain (NfL) and 18 kDa translocator protein in early psychosis and its putative high-riskKankana Nisha Aji, Giulia Cisbani, Ana Weidenauer, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 13, 2017
Imaging Microglial Activation in Individuals at Clinical High Risk for Psychosis: an In Vivo PET Study with [<sup>18</sup>F]FEPPASina Hafizi, Tania Da Silva, Cory Gerritsen, et al.
Pageof 7